India, Feb. 17 -- Biotechnology company Oxford Biomedica Plc (OXB.L) announced on Monday that it expects to record revenues between 127 million pounds to 129 million pounds in fiscal 2024. The expected revenue growth is in line with the company's outlook of between 126 million pounds and 134 million pounds.
The company added that the revenue numbers are 42 percent-44 percent higher than full-year 2023. Oxford Biomedica also expects an organic growth of between 78 percent to 81 percent in fiscal 2024, which excludes the impact of the acquisition of OXB France and the loss of revenues from Homology Medicines, Inc.
For the year ahead, the company is projecting a mid to high-teens operating EBITDA loss. This is mainly due to the integration o...